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Abstract: Ipilimumab is a monoclonal antibody against the inhibitory CTLA-4
receptor expressed on T cells. It provokes an upregulation of the immune system.
This substance was approved by the US Food and Drug Administration in 2011
and is since increasingly used as a targeted therapeutic approach for metastasized
melanoma. Ipilimumab is known to cause neuroendocrine disorders, such as
hypophysitis and adrenal insufficiency. Our case of a 79-year-old patient repre-
sents an important imaging pitfall. Imaging findings of newly symmetrically
and smoothly enlarged, hypermetabolic adrenal glands in the setting of previous
ipilimumab therapy represent drug-induced adrenalitis and not metastatic disease.
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FIGURE 1. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging over 8 months
in a 79-year-old man with metastasized melanoma. Axial nonenhanced CT image (A) and axial 18F-FDG-PET/CT image (B) show a
normal-sized left adrenal gland with normal FDG uptake (arrow; maximum standardized uptake value (SUVmax), 2.4).
Adrenocorticotropic hormone (ACTH) and cortisol concentrations were normal. Therapy with ipilimumab was started 1 month later
and continued for a total of twomonths, corresponding to 4 cycles. Fourmonths after the first 18F-FDG-PET/CTwas acquired, follow-up
CT image (C) and 18F-FDG-PET/CT image (D) show a smooth thickening of the left adrenal gland with intense FDG uptake (arrow;
SUVmax, 21.3). The right adrenal gland is seen as well and shows the same imaging features (arrowhead). The lack of nodularity and
mass is inconsistent with metastatic disease to the adrenals, which is a major concern in metastasized melanoma. The absence of
hyperdensity argues against acute adrenal hemorrhage, which is also known to cause increased FDG uptake, and may occur bilaterally.
At this time point, the patient’s cortisol level was elevated (579 nmol/L; reference range, 64–327 nmol/L), despite a lack of clinical
symptoms. Another 4 months later, shape and metabolic activity of both the left adrenal glands have returned to normal (arrow
showing left adrenal gland; SUVmax, 2.1; right adrenal partially depicted), as seen on axial nonenhanced CT image (E) and axial
18F-FDG-PET/CT image (F). There was no evidence of adrenal dysfunction at this time point anymore. Endocrinopathy accounts for
4% to 8% of all adverse effects related to ipilimumab treatment.1 Ipilimumab is well known for the induction of lymphocytic
hypophysitis and anterior panhypopituitarism, which may finally lead to secondary adrenal gland insufficiency in severe cases.2–5 Other
adverse effects include colitis, hepatitis, and reactivation of sarcoid.6–9 The usual onset of neuroendocrine disorders occurs between
6 and 12 weeks after initializing treatment.10–12 In our patient, the time interval of 3 months between the start of ipilimumab and
the advent of enlarged, hypermetabolic adrenal glands is in line with this period. CT findings of ipilimumab-related autoimmune
adrenalitis have hitherto been described in one single case report.13 Primary adrenal insufficiency is reported as a rare complication
in a few clinical studies, probably representing a sequela of previous adrenalitis.14,15 In conclusion, 18F-FDG-PET/CT findings of
symmetrically and smoothly enlarged, hypermetabolic adrenal glands after ipilimumab therapy should raise the suspicion of
drug-induced adrenalitis and may imply a monitoring of the patient's adrenal function.
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